Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation

Somatic mutations of STK11 or KEAP1 are associated with poor clinical outcomes for advanced non-small-cell lung cancer (aNSCLC) patients receiving immune checkpoint inhibitors (ICIs), chemotherapy, or targeted therapy. Which treatment regimens work better for STK11 or KEAP1 mutated (SKmut) aNSCLC pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Nie, Wei, Gan, Lu, Wang, Xin, Gu, Kai, Qian, Fang-Fei, Hu, Min-Juan, Zhang, Ding, Chen, Shi-Qing, Lu, Jun, Cao, Shu-Hui, Li, Jing-Wen, Wang, Yue, Zhang, Bo, Wang, Shu-Yuan, Li, Chang-Hui, Yang, Ping, Xu, Mi–Die, Zhang, Xue-Yan, Zhong, Hua, Han, Bao-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833760/
https://www.ncbi.nlm.nih.gov/pubmed/33537171
http://dx.doi.org/10.1080/2162402X.2020.1865670

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833760/
https://www.ncbi.nlm.nih.gov/pubmed/33537171
http://dx.doi.org/10.1080/2162402X.2020.1865670

Ejemplares similares